Lenalidomide (Revlimid) for Newly Diagnosed Multiple Myeloma – First Line

featured image
Interventions: Lenalidomide (Revlimid)
Indications: Multiple myeloma (MM)
Year: 2017

Lenalidomide in combination with bortezomib and dexamethasone is being developed for the treatment of adult patients with MM. While each of these drugs are already approved for treating a range of malignant blood diseases, the combination of the three drugs has shown significant potential particularly for the treatment of newly diagnosed MM. If approved, it will offer an additional treatment option for adult patients whether or not they are eligible or ineligible for bone marrow transplant.